Medical Marijuana, Inc. Subsidiary HempMeds® Brasil Announces Sponsorship of International Medicinal Cannabis Seminar in Brazil

SAN DIEGO, May 16, 2018 — Medical Marijuana, Inc. (OTC:MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Brasil is a main sponsor for the “A Look Into the Future” International Medicinal Seminar in Rio de Janeiro, Brazil, on May 18-19.

HempMeds® Brasil was the first company authorized by ANVISA to import a cannabidiol (CBD)-based product into Brazil for those suffering from various specific medical conditions.

“Our international presence is important to the future of the company because we want to show that we care about access to CBD around the world, not just in the U.S.,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus.

The “A Look Into the Future” International Medicinal Seminar was organized to discuss access to cannabis in the country and its insertion into public health. During the two-day event, doctors from across the globe will share their efforts to pioneer cannabis research. There will also be several patient panels where medical cannabis users will share testimonials on how cannabis has influenced their health.

During the event, a manifesto will be signed and presented by public and private companies, associations and self-cultivation experts to urge Brazilian authorities to regulate the cultivation and domestic production of cannabis for therapeutic purposes.

“Our Company is proud to sponsor such a prestigious seminar,” said HempMeds® Brasil Vice President Caroline Heinz. “We hope that the manifesto being presented at the event will present itself as a call-to-action for the country’s authorities to help us create a safe and legal cannabis market.”

For more information about the company’s participation in the symposium, please follow @HempMedsBrasil on Facebook.

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit

To see Medical Marijuana, Inc.’s corporate video, click here.

Shareholders and consumers are also encouraged to buy CBD oil and other products at Medical Marijuana, Inc.’s shop.

About HempMeds® Brazil

HempMeds® Brazil was the first company to receive approval from the National Sanitary Surveillance Agency (Anvisa) to import a product based on cannabidiol, a substance derived from hemp, a plant of the genus Cannabis. Currently, it is authorized to supply its products, which help in the control of diseases such as epilepsy, Parkinson’s, chronic pain and multiple sclerosis, under medical prescription. For these indications, the products can be subsidized by the Brazilian government. HempMeds® Brazil works on additional approvals for other indications. About HempMeds® Brazil and all its products with natural hemp oil:


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.


Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.


Andrew Hard

Chief Executive Officer, CMW Media

P: 858-264-6600

E: [email protected]